Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Buy
59
ORMP Quote, Financials, Valuation and Earnings
Last price:
$3.53
Seasonality move
:
12.3%
Day range:
$3.34 - $3.47
52-week range:
$1.82 - $3.71
Dividend yield:
7.38%
P/E ratio:
3.38x
P/S ratio:
70.57x
P/B ratio:
0.66x
Volume:
217.8K
Avg. volume:
278.5K
1-year change:
47.39%
Market cap:
$134.9M
Revenue:
--
EPS (TTM):
$1.00
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-- | -$0.07 | -- | -75% | $3.25 |
|
BMY
Bristol Myers Squibb Co.
|
$12.3B | $1.42 | -7.02% | 17.19% | $56.96 |
|
INVA
Innoviva, Inc.
|
$101.5M | $0.43 | 6.61% | 50.34% | $32.50 |
|
LFWD
Lifeward Ltd.
|
$7.9M | -$0.09 | 4.27% | -94.81% | $7.25 |
|
NKTR
Nektar Therapeutics
|
$10.4M | -$2.90 | -64.24% | -1474.64% | $114.43 |
|
TBPH
Theravance Biopharma, Inc.
|
$43M | -$0.05 | 129.3% | -80.69% | $26.71 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals, Inc.
|
$3.39 | $3.25 | $134.9M | 3.38x | $0.25 | 7.38% | 70.57x |
|
BMY
Bristol Myers Squibb Co.
|
$54.65 | $56.96 | $111.3B | 18.45x | $0.63 | 4.56% | 2.32x |
|
INVA
Innoviva, Inc.
|
$19.56 | $32.50 | $1.5B | 14.03x | $0.00 | 0% | 3.84x |
|
LFWD
Lifeward Ltd.
|
$0.67 | $7.25 | $11.9M | -- | $0.00 | 0% | 0.32x |
|
NKTR
Nektar Therapeutics
|
$37.11 | $114.43 | $642M | -- | $0.00 | 0% | 38.27x |
|
TBPH
Theravance Biopharma, Inc.
|
$20.24 | $26.71 | $1B | 35.98x | $0.00 | 0% | 12.70x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals, Inc.
|
0.42% | -0.230 | 0.8% | 22.01x |
|
BMY
Bristol Myers Squibb Co.
|
73.34% | -0.335 | 56.92% | 0.94x |
|
INVA
Innoviva, Inc.
|
20.41% | 0.020 | 18.98% | 12.93x |
|
LFWD
Lifeward Ltd.
|
1.82% | -2.286 | 1.98% | 0.94x |
|
NKTR
Nektar Therapeutics
|
66.26% | 7.327 | 16.97% | 4.07x |
|
TBPH
Theravance Biopharma, Inc.
|
16.08% | 0.446 | 6.03% | 9.30x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ORMP
Oramed Pharmaceuticals, Inc.
|
-$31K | -$2.4M | 27.4% | 27.49% | -225% | -$2M |
|
BMY
Bristol Myers Squibb Co.
|
$8.1B | $3.8B | 8.82% | 34.7% | 31.46% | $6B |
|
INVA
Innoviva, Inc.
|
$75.5M | $34.6M | 10.86% | 17.06% | 31.08% | $48.6M |
|
LFWD
Lifeward Ltd.
|
$2.7M | -$3.1M | -146.07% | -150.63% | -50.69% | -$3.8M |
|
NKTR
Nektar Therapeutics
|
$11.6M | -$31.5M | -54.14% | -327.67% | -267.45% | -$48.9M |
|
TBPH
Theravance Biopharma, Inc.
|
$18.6M | -$6.5M | 11.74% | 14.9% | -32.29% | -$6.5M |
Oramed Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns ORMP or BMY?
Bristol Myers Squibb Co. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of 17.96%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Bristol Myers Squibb Co.'s return on equity of 34.7%.
Company Gross Margin Earnings Per Share Invested Capital ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M BMYBristol Myers Squibb Co.66% $1.08 $69.6B -
What do Analysts Say About ORMP or BMY?
Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -4.13%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $56.96 which suggests that it could grow by 4.22%. Given that Bristol Myers Squibb Co. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Bristol Myers Squibb Co. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORMPOramed Pharmaceuticals, Inc.0 0 0 BMYBristol Myers Squibb Co.5 17 1 -
Is ORMP or BMY More Risky?
Oramed Pharmaceuticals, Inc. has a beta of 1.195, which suggesting that the stock is 19.511% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.288, suggesting its less volatile than the S&P 500 by 71.215%.
-
Which is a Better Dividend Stock ORMP or BMY?
Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.38%. Bristol Myers Squibb Co. offers a yield of 4.56% to investors and pays a quarterly dividend of $0.63 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 54.44% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios ORMP or BMY?
Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.2B. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is lower than Bristol Myers Squibb Co.'s net income of $2.2B. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.38x while Bristol Myers Squibb Co.'s PE ratio is 18.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 70.57x versus 2.32x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORMPOramed Pharmaceuticals, Inc.70.57x 3.38x -- $48.4M BMYBristol Myers Squibb Co.2.32x 18.45x $12.2B $2.2B
-
Which has Higher Returns ORMP or INVA?
Innoviva, Inc. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of 80.81%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Innoviva, Inc.'s return on equity of 17.06%.
Company Gross Margin Earnings Per Share Invested Capital ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M INVAInnoviva, Inc.67.87% $1.08 $1.3B -
What do Analysts Say About ORMP or INVA?
Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -4.13%. On the other hand Innoviva, Inc. has an analysts' consensus of $32.50 which suggests that it could grow by 66.16%. Given that Innoviva, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Innoviva, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORMPOramed Pharmaceuticals, Inc.0 0 0 INVAInnoviva, Inc.3 0 1 -
Is ORMP or INVA More Risky?
Oramed Pharmaceuticals, Inc. has a beta of 1.195, which suggesting that the stock is 19.511% more volatile than S&P 500. In comparison Innoviva, Inc. has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.652%.
-
Which is a Better Dividend Stock ORMP or INVA?
Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.38%. Innoviva, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Innoviva, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORMP or INVA?
Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Innoviva, Inc. quarterly revenues of $111.3M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is lower than Innoviva, Inc.'s net income of $89.9M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.38x while Innoviva, Inc.'s PE ratio is 14.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 70.57x versus 3.84x for Innoviva, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORMPOramed Pharmaceuticals, Inc.70.57x 3.38x -- $48.4M INVAInnoviva, Inc.3.84x 14.03x $111.3M $89.9M
-
Which has Higher Returns ORMP or LFWD?
Lifeward Ltd. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of -51.17%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Lifeward Ltd.'s return on equity of -150.63%.
Company Gross Margin Earnings Per Share Invested Capital ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M LFWDLifeward Ltd.43.7% -$0.20 $13M -
What do Analysts Say About ORMP or LFWD?
Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -4.13%. On the other hand Lifeward Ltd. has an analysts' consensus of $7.25 which suggests that it could grow by 981.12%. Given that Lifeward Ltd. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Lifeward Ltd. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORMPOramed Pharmaceuticals, Inc.0 0 0 LFWDLifeward Ltd.1 0 0 -
Is ORMP or LFWD More Risky?
Oramed Pharmaceuticals, Inc. has a beta of 1.195, which suggesting that the stock is 19.511% more volatile than S&P 500. In comparison Lifeward Ltd. has a beta of 0.002, suggesting its less volatile than the S&P 500 by 99.817%.
-
Which is a Better Dividend Stock ORMP or LFWD?
Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.38%. Lifeward Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Lifeward Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORMP or LFWD?
Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Lifeward Ltd. quarterly revenues of $6.2M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Lifeward Ltd.'s net income of -$3.2M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.38x while Lifeward Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 70.57x versus 0.32x for Lifeward Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORMPOramed Pharmaceuticals, Inc.70.57x 3.38x -- $48.4M LFWDLifeward Ltd.0.32x -- $6.2M -$3.2M
-
Which has Higher Returns ORMP or NKTR?
Nektar Therapeutics has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of -301.29%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Nektar Therapeutics's return on equity of -327.67%.
Company Gross Margin Earnings Per Share Invested Capital ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M NKTRNektar Therapeutics98.34% -$1.87 $252.2M -
What do Analysts Say About ORMP or NKTR?
Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -4.13%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 208.35%. Given that Nektar Therapeutics has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Nektar Therapeutics is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORMPOramed Pharmaceuticals, Inc.0 0 0 NKTRNektar Therapeutics6 1 0 -
Is ORMP or NKTR More Risky?
Oramed Pharmaceuticals, Inc. has a beta of 1.195, which suggesting that the stock is 19.511% more volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.
-
Which is a Better Dividend Stock ORMP or NKTR?
Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.38%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORMP or NKTR?
Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.38x while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 70.57x versus 38.27x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORMPOramed Pharmaceuticals, Inc.70.57x 3.38x -- $48.4M NKTRNektar Therapeutics38.27x -- $11.8M -$35.5M
-
Which has Higher Returns ORMP or TBPH?
Theravance Biopharma, Inc. has a net margin of -382.1% compared to Oramed Pharmaceuticals, Inc.'s net margin of 18.08%. Oramed Pharmaceuticals, Inc.'s return on equity of 27.49% beat Theravance Biopharma, Inc.'s return on equity of 14.9%.
Company Gross Margin Earnings Per Share Invested Capital ORMPOramed Pharmaceuticals, Inc.0.65% $1.13 $203.2M TBPHTheravance Biopharma, Inc.92.96% $0.07 $277.3M -
What do Analysts Say About ORMP or TBPH?
Oramed Pharmaceuticals, Inc. has a consensus price target of $3.25, signalling downside risk potential of -4.13%. On the other hand Theravance Biopharma, Inc. has an analysts' consensus of $26.71 which suggests that it could grow by 31.99%. Given that Theravance Biopharma, Inc. has higher upside potential than Oramed Pharmaceuticals, Inc., analysts believe Theravance Biopharma, Inc. is more attractive than Oramed Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORMPOramed Pharmaceuticals, Inc.0 0 0 TBPHTheravance Biopharma, Inc.5 2 0 -
Is ORMP or TBPH More Risky?
Oramed Pharmaceuticals, Inc. has a beta of 1.195, which suggesting that the stock is 19.511% more volatile than S&P 500. In comparison Theravance Biopharma, Inc. has a beta of 0.139, suggesting its less volatile than the S&P 500 by 86.12%.
-
Which is a Better Dividend Stock ORMP or TBPH?
Oramed Pharmaceuticals, Inc. has a quarterly dividend of $0.25 per share corresponding to a yield of 7.38%. Theravance Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Oramed Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theravance Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORMP or TBPH?
Oramed Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theravance Biopharma, Inc. quarterly revenues of $20M. Oramed Pharmaceuticals, Inc.'s net income of $48.4M is higher than Theravance Biopharma, Inc.'s net income of $3.6M. Notably, Oramed Pharmaceuticals, Inc.'s price-to-earnings ratio is 3.38x while Theravance Biopharma, Inc.'s PE ratio is 35.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Oramed Pharmaceuticals, Inc. is 70.57x versus 12.70x for Theravance Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORMPOramed Pharmaceuticals, Inc.70.57x 3.38x -- $48.4M TBPHTheravance Biopharma, Inc.12.70x 35.98x $20M $3.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Palantir Stock Going to Crash?
AI and data analytics major Palantir (NASDAQ:PLTR) has become something…
Why Did AMD Stock Go Up?
Since January 9th, shares of chipmaker AMD (NASDAQ:AMD) have been…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Sell
47
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
70
BNAI alert for Jan 26
Brand Engagement Network, Inc. [BNAI] is up 268.33% over the past day.
Buy
56
INTC alert for Jan 26
Intel Corp. [INTC] is down 6.04% over the past day.
Buy
64
BNR alert for Jan 26
Burning Rock Biotech Ltd. [BNR] is up 1.45% over the past day.
